Overview

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Bioequivalence study between two inhaler products of ffluticasone propionate inhalation powder
Phase:
Phase 1
Details
Lead Sponsor:
Respirent Pharmaceuticals Co Ltd.
Collaborator:
Becro Ltd.
Treatments:
Fluticasone
Xhance